The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
CompletedOBSERVATIONAL
Enrollment
100
Participants
Timeline
Start Date
March 31, 2015
Primary Completion Date
December 31, 2019
Study Completion Date
December 31, 2019
Conditions
Non-small Cell Lung Cancer (NSCLC)
Trial Locations (1)
19104
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
All Listed Sponsors
lead
Abramson Cancer Center at Penn Medicine
OTHER
NCT02380196 - The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter